ABVC Biopharma, Inc. has announced a successful private placement of senior convertible promissory notes, raising a total of $3.39 million. This funding is expected to strengthen the company's financial position as it continues to develop its pharmaceutical products.
The private placement, filed under SEC accession number 0001213900-26-118072, reflects ABVC's ongoing efforts to secure capital in a competitive market. The company issued notes with an aggregate principal amount of $4.1 million, which were sold at a 17.5% original issue discount.
About ABVC Biopharma
ABVC Biopharma, Inc. is a corporation based in Fremont, California, specializing in pharmaceutical preparations, classified under SIC code 2834. The company is listed on the Nasdaq and OTC exchanges under the tickers ABVC and ECOC. As a smaller reporting company, ABVC aims to leverage its innovative solutions in the biotechnology sector.
Details from the Filing
The SEC filing indicates that the total offering amount was $3,387,500, with all amounts sold and no remaining. The company reported that nine investors participated in the offering, and no non-accredited investors were involved. WallachBeth Capital, LLC acted as the exclusive placement agent for this transaction, receiving a cash fee of 7% of the gross proceeds.
The amounts reported reflect the aggregate purchase price of $3,387,500 paid for senior convertible promissory notes with an aggregate principal amount of $4,106,060, issued at a 17.5% original issue discount.
Impact on Stakeholders
This successful fundraising effort may positively impact ABVC's stakeholders, including its executive officers and directors, who are primarily based in Fremont, California. The funds raised will likely be directed toward enhancing the company's research and development initiatives, potentially leading to new product offerings and improved market positioning.
What's Next for ABVC?
The filing does not specify what happens next for ABVC Biopharma after this successful placement. However, the company is expected to continue its focus on advancing its pharmaceutical projects and exploring further financing opportunities to support its growth strategy.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










